Analytik Jena Announces Preliminary Figures for the 2009/2010 Financial Year

• New sales record achieved at EUR 80.2 m
• Earnings negatively impacted by one-off effects and below expectations
• Dividend of EUR 0.15 per share proposed for the first time

Jena, November 22, 2010 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) achieved sales of EUR 80.2 m in the 2009/2010 financial year (previous year: EUR 71.2 m) and in doing so once again exceeded the record sales of the previous year by 12.8%. The manufacturer of analytical, bioanalytical and optical systems and molecular diagnostic reagents continued to post above-average growth in the Life Science segment in particular and stable sales development in the core business of Analytical Instrumentation.

In terms of operating results Analytik Jena fell short of the previous year’s performance. The Group recorded EBIT of EUR 3.1 m in the financial year just ended (previous year: EUR 6.3 m), equivalent to a year-on-year decline of about 50.0%. Several one-off effects of in total more than EUR 2.0 m are included in the results such as the winding-up of CyBio Japan and higher costs for establishing a sales network for the Life Science segment in important Asian growth markets such as Japan and China. Further negative impact on earnings came from the gross margin, that is stagnant despite the strong US-Dollar, partially from capacity related factors with view to the continued weak business development in Optics, from high pricing pressure in all three business units as well as from ongoing investigations at the minority holding AJZ Engineering GmbH.

Earnings per share in the past financial year amount to EUR 0.34. (previous year: EUR 0.11). It should be noted here, that the previous year`s financial statements had to be adjusted as a result of the tax audit for 2003 to 2007 and a reclassification of currency translation. Accordingly earnings per share in the past financial year changed to EUR 0.11 (previously: EUR 0.51 EUR).

"Although in our anniversary year we again achieved double-digit sales growth with an operating cash flow of EUR 1.5 m, earnings have remained below our expectations. We see good progress in the integration of CyBio AG and Biometra GmbH into the Group and in the increasing internationalization of the Life Science segment," said Klaus Berka, CEO of Analytik Jena AG. "We expect to be able to increase our profitability and earnings significantly again in the financial year currently under way."

Based on the good results of the past few years, the Company will propose to the Supervisory Board that a dividend payment of EUR 0.15 per share be included in the agenda for the Annual General Meeting to be held on April 19, 2011.

The figures given in the announcement are preliminary figures. The final results for the 2009/2010 financial year (as at September 30) will be announced by the Group on December 16, 2010.